New 2-Month TB pill cocktail could replace 6-Month regimen
NCT ID NCT06905522
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new ultra-short treatment for both drug-sensitive and drug-resistant tuberculosis (TB). The goal is to see if a 2-3 month regimen works as well as or better than the standard 4-6 month treatment. About 610 adults with active TB will take part. The approach could simplify care, lower costs, and reduce side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIDRUG RESISTANT PULMONARY TUBERCULOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Chest Hospital of Capital Medical University
RECRUITINGBeijing, China
-
Shenzhen Third People's Hospital
RECRUITINGShenzhen, China
-
The Sixth People's Hospital of the Xinjiang Uygur Autonomous Region
RECRUITINGÜrümqi, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new patient cohort unlock the secrets of TB treatment success?
- Shorter TB treatment: a 4-Month regimen put to the test
- Lung damage after TB: a new study tests whether rehabilitation can restore breathing and quality of life
- Can a more powerful antibiotic clear TB faster? a trial puts rifapentine to the test.
- Could a simple screening strategy uncover hidden TB in COPD patients?
- Talking it out: could counseling be the key to beating TB?